Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE
- Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
- Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
- Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
- Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
- Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19
- Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)
- VAccination in Early and ADvanced Prostate caNCEr
- MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
- Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
- QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age
- Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
- Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
- Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
- A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers
- A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants
- Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination
- Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
- Research In Viral Eradication of HIV Reservoirs
- Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
- GVAX vs. Placebo for MDS/AML After Allo HSCT
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
- Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
- Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso
- Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
- Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
- Phase 1 Safety Study of Two Experimental HIV Vaccines
- Experimental Vaccine for Prevention of Ebola Virus Infection
- Adenovirus Vaccine for Malaria
- Phase I Study of Vaccination Schedule of Experimental HIV Vaccines
- Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients
- "Prime-Boost" Vaccine Schedule for Prevention of HIV Infection
- Vaccine Treatment for HIV-Infection
- HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers
- Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
- Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers
- Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Clinical trials list
click for details